Targeted Delivery to Dying Cells Through P-Selectin-PSGL-1 Axis: A Promising Strategy for Enhanced Drug Efficacy in...

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Cell Biology

Background:

• Current tissue-specific drug delivery systems face challenges in differentiating between normal and dying cells within diseased organs.
• Targeted delivery to dying cells is crucial for minimizing off-target effects and improving therapeutic efficacy.
• P-selectin glycoprotein ligand-1 (PSGL-1) was identified as a potential universal marker on dying cells.

Purpose of the Study:

• To develop and evaluate a targeted drug delivery system specifically for dying cells.
• To utilize the P-selectin-PSGL-1 axis for selective delivery of therapeutic agents.
• To assess the efficacy of P-selectin-conjugated liposomes in a liver injury model.

Main Methods:

• In vitro identification of dying cell surface markers, focusing on PSGL-1.
• Conjugation of P-selectin to liposomes to enhance binding to PSGL-1 on dying cells.
• In vivo assessment using a thioacetamide (TAA)-induced mouse model of hepatitis and liver damage.

Main Results:

• P-selectin-conjugated liposomes demonstrated significantly higher binding efficiency to dying cells compared to control proteins.
• In vivo, P-selectin liposomes successfully delivered cargo (fluorescent dye, apoptosis inhibitor) to TAA-damaged livers in wild-type mice.
• P-selectin conjugation enhanced drug delivery efficiency by approximately 100-fold, leading to improved therapeutic outcomes in liver injury.

Conclusions:

• P-selectin-based liposomes represent a promising strategy for targeted drug delivery to dying cells.
• This approach can enhance therapeutic efficacy and reduce off-target effects in diseased tissues.
• The P-selectin-PSGL-1 targeting system holds potential for both diagnostic and therapeutic applications at the cellular level.